P302

Inorg. Chem., 2025, 64, 16192-16203.

Synthesis and Biological Evaluation of Itraconazole Derivatives: Design in an Old Scaffold.

https://doi.org/10.1021/acs.inorgchem.5c02730

P300

RSC Med. Chem. 2025, 16, 3746–3763.

Pharmacophore-guided optimization of the hit compound CTN1122 in the design of promising imidazo[1,2-a]pyrazine derivatives targeting the casein kinase 1 for antileishmanial therapy

https://doi.org/10.1039/D5MD00257E

P290

ChemMedChem. 2025, 20, e202400862.

Investigating the C2 modulation of the imidazo[1,2-a]pyrazine-based hit compound CTN1122: synthesis, in vitro antileishmanial activity, cytotoxicity and casein kinase 1 inhibition.

https://doi.org/10.1002/cmdc.202400862

P280

Chem. Biodiversity 2024, e202300563

Chemical Composition, Antifungal, Antioxidant, and Hemolytic Activities of Morrocan Thymus capitatus Essential Oil.

https://doi.org/10.1002/cbdv.202300563

P270

J. Fungi 2023, 9, 430.

The mortality attributable to candidemia in C. auris is higher than that in other Candida species: Myth or reality?

https://doi.org/10.3390/jof9040430

P269

Nat. Prod. Res. 2023

Phytochemical, antileishmanial, antifungal and cytotoxic profiles of Thymelaea tartonraira (L.) All. extracts.

https://doi.org/10.1080/14786419.2023.2252153

P251

Microorganisms. 2022, 10, 938.

Prototheca infections and ecology from a One Health perspective.

https://doi.org/10.3390/microorganisms10050938

P234

Med. Chem. Res. 2021, 30, 152-162.

Antimicrobial and anti-leishmanial activities of extracts and some constituents from the leaves of Solanum chrysotrichum Schldl.

doi: 10.1007/s00044-020-02648-8

P231

Eur. J. Med. Chem. 2021, 210, 112956.

In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L. major casein kinase 1 inhibition.

doi: 10.1016/j.ejmech.2020.112956

P212

Eur. J. Med. Chem. 2020, 189, 112082.

New Azole Antifungals with a Fused Triazinone Scaffold.

doi: 10.1016/j.ejmech.2020.112082

P208

J. Enzym. Inhib. Med. Chem. 2020, 35, 398-403.

Biological exploration of a novel 1,2,4-triazole-indole hybrid molecule as antifungal agent.

doi: 10.1080/14756366.2019.1705292

P136

Eur. J. Med. Chem. 2015, 103, 381-395.

Synthesis, antileishmanial activity and cytotoxicity of 2,3-diaryl- and 2,3,8-trisubstituted imidazo[1,2-a]pyrazines.

doi: 10.1016/j.ejmech.2015.09.002

P114

ACS Med. Chem. Lett., 2013, 4, 288-292.

Discovery of a novel broad-spectrum antifungal agent, derived from albaconazole.

P108

Eur. J. Med. Chem., 2012, 58, 543-556.

Synthesis and biological evaluation of 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents.

P96

ChemMedChem, 2011, 6, 1806-1815.

Design, synthesis and biological evaluation of 1-[(biarylmethyl)methylamino]-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ols as potent antifungal agents: new insights into structure-activity relationships.

P91

ChemMedChem, 2011, 6, 816-825.

Design, synthesis and in vitro antifungal activity of 1-[(4-substituted benzyl)methylamino]-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ols.

P87

J. Enzym. Inhib. Med. Chem., 2011, 26(2), 261-269.

Synthesis and in vitro antifungal evaluation of 2-(2,4-difluorophenyl)-1-[(1H-indol-3-ylmethyl)methylamino]-3-(1H-1,2,4-triazol-1-yl)propan-2-ols.

P79

Bioorg. Med. Chem. Lett., 2009, 19(20), 5833-5836.

Design of new antifungal agents: synthesis and evaluation of 1-[(1H-indol-5-ylmethyl)amino]-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ols.

P77

J. Enz. Inh. Med. Chem., 2009, 24(5), 1067-1075.

Design, synthesis and evaluation of 3-(imidazol-1-ylmethyl)indoles as antileishmanial agents. Part II.

P74

Bioorg. Med. Chem. Lett., 2009, 19(2), 301-304

Synthesis and structure-activity relationships of 2-phenyl-1-[(pyridinyl- and piperidinylmethyl)amino]-3-(1H-1,2,4-triazol-1-yl)propan-2-ols as antifungal agents.